{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T10:44:57Z","timestamp":1791888297496,"version":"4.3.4"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2015,3,23]],"date-time":"2015-03-23T00:00:00Z","timestamp":1427068800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1038\/bmt.2015.52","type":"journal-article","created":{"date-parts":[[2015,3,23]],"date-time":"2015-03-23T14:34:59Z","timestamp":1427121299000},"page":"781-789","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":336,"title":["Sinusoidal obstruction syndrome\/veno-occlusive disease: current situation and perspectives\u2014a position statement from the European Society for Blood and Marrow Transplantation (EBMT)"],"prefix":"10.1038","volume":"50","author":[{"given":"M","family":"Mohty","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Malard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Abecassis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Aerts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A S","family":"Alaskar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Aljurf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Arat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Bader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Baron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Bazarbachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Blaise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Ciceri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Corbacioglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J-H","family":"Dalle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R F","family":"Duarte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Huynh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Masszi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Michallet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Nagler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"NiChonghaile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Pagluica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0369-8515","authenticated-orcid":false,"given":"C","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F B","family":"Petersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P G","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Ruutu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B N","family":"Savani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Wallhult","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I","family":"Yakoub-Agha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Carreras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,3,23]]},"reference":[{"key":"BFbmt201552_CR1","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1034\/j.1600-0609.2000.9r200.x","volume":"64","author":"E Carreras","year":"2000","unstructured":"Carreras E . Veno-occlusive disease of the liver after hemopoietic cell transplantation. Eur J Haematol 2000; 64: 281\u2013291.","journal-title":"Eur J Haematol"},{"key":"BFbmt201552_CR2","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1038\/bmt.2011.65","volume":"46","author":"E Carreras","year":"2011","unstructured":"Carreras E, Diaz-Ricart M . The role of the endothelium in the short-term complications of hematopoietic SCT. Bone Marrow Transplant 2011; 46: 1495\u20131502.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt201552_CR3","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1002\/hep.1840040121","volume":"4","author":"GB McDonald","year":"1984","unstructured":"McDonald GB, Sharma P, Matthews DE, Shulman HM, Thomas ED . Venocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors. Hepatology 1984; 4: 116\u2013122.","journal-title":"Hepatology"},{"key":"BFbmt201552_CR4","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1097\/00007890-198712000-00011","volume":"44","author":"RJ Jones","year":"1987","unstructured":"Jones RJ, Lee KS, Beschorner WE, Vogel VG, Grochow LB, Braine HG et al. Venoocclusive disease of the liver following bone marrow transplantation. Transplantation 1987; 44: 778\u2013783.","journal-title":"Transplantation"},{"key":"BFbmt201552_CR5","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.bbmt.2009.08.024","volume":"16","author":"JA Coppell","year":"2010","unstructured":"Coppell JA, Richardson PG, Soiffer R, Martin PL, Kernan NA, Chen A et al. Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome. Biol Blood Marrow Transplant 2010; 16: 157\u2013168.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt201552_CR6","first-page":"3599","volume":"92","author":"E Carreras","year":"1998","unstructured":"Carreras E, Bertz H, Arcese W, Vernant JP, Tomas JF, Hagglund H et al. Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for Blood and Marrow Transplantation. European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party. Blood 1998; 92: 3599\u20133604.","journal-title":"Blood"},{"key":"BFbmt201552_CR7","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1016\/j.bbmt.2011.06.006","volume":"17","author":"E Carreras","year":"2011","unstructured":"Carreras E, Diaz-Beya M, Rosinol L, Martinez C, Fernandez-Aviles F, Rovira M . The incidence of veno-occlusive disease following allogeneic hematopoietic stem cell transplantation has diminished and the outcome improved over the last decade. Biol Blood Marrow Transplant 2011; 17: 1713\u20131720.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt201552_CR8","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1111\/bjh.13215","volume":"168","author":"E Carreras","year":"2014","unstructured":"Carreras E . How I manage sinusoidal obstruction syndrome after haematopoietic cell transplantation. Br J Haematol 2014; 168: 481\u2013491.","journal-title":"Br J Haematol"},{"key":"BFbmt201552_CR9","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1038\/sj.bmt.1701264","volume":"21","author":"G Eissner","year":"1998","unstructured":"Eissner G, Multhoff G, Holler E . Influence of bacterial endotoxin on the allogenicity of human endothelial cells. Bone Marrow Transplant 1998; 21: 1286\u20131288.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt201552_CR10","first-page":"578","volume":"89","author":"B Fuste","year":"2004","unstructured":"Fuste B, Mazzara R, Escolar G, Merino A, Ordinas A, Diaz-Ricart M . Granulocyte colony-stimulating factor increases expression of adhesion receptors on endothelial cells through activation of p38 MAPK. Haematologica 2004; 89: 578\u2013585.","journal-title":"Haematologica"},{"key":"BFbmt201552_CR11","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1016\/j.transproceed.2004.05.073","volume":"36","author":"F Mercanoglu","year":"2004","unstructured":"Mercanoglu F, Turkmen A, Kocaman O, Pinarbasi B, Dursun M, Selcukbiricik F et al. Endothelial dysfunction in renal transplant patients is closely related to serum cyclosporine levels. Transplant Proc 2004; 36: 1357\u20131360.","journal-title":"Transplant Proc"},{"key":"BFbmt201552_CR12","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1055\/s-2002-23204","volume":"22","author":"LD DeLeve","year":"2002","unstructured":"DeLeve LD, Shulman HM, McDonald GB . Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease). Semin Liver Dis 2002; 22: 27\u201342.","journal-title":"Semin Liver Dis"},{"key":"BFbmt201552_CR13","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/j.bbmt.2010.02.008","volume":"16","author":"M Palomo","year":"2010","unstructured":"Palomo M, Diaz-Ricart M, Carbo C, Rovira M, Fernandez-Aviles F, Martine C et al. Endothelial dysfunction after hematopoietic stem cell transplantation: role of the conditioning regimen and the type of transplantation. Biol Blood Marrow Transplant 2010; 16: 985\u2013993.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt201552_CR14","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.bbmt.2009.01.013","volume":"15","author":"M Palomo","year":"2009","unstructured":"Palomo M, Diaz-Ricart M, Carbo C, Rovira M, Fernandez-Aviles F, Escolar G et al. The release of soluble factors contributing to endothelial activation and damage after hematopoietic stem cell transplantation is not limited to the allogeneic setting and involves several pathogenic mechanisms. Biol Blood Marrow Transplant 2009; 15: 537\u2013546.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt201552_CR15","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.bbmt.2007.10.008","volume":"14","author":"KR Cooke","year":"2008","unstructured":"Cooke KR, Jannin A, Ho V . The contribution of endothelial activation and injury to end-organ toxicity following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2008; 14: 23\u201332.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt201552_CR16","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.beha.2008.02.003","volume":"21","author":"BC Biedermann","year":"2008","unstructured":"Biedermann BC . Vascular endothelium and graft-versus-host disease. Best Pract Res Clin Haematol 2008; 21: 129\u2013138.","journal-title":"Best Pract Res Clin Haematol"},{"key":"BFbmt201552_CR17","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1016\/j.bbmt.2013.07.001","volume":"19","author":"A Carmona","year":"2013","unstructured":"Carmona A, Diaz-Ricart M, Palomo M, Molina P, Pino M, Rovira M et al. Distinct deleterious effects of cyclosporine and tacrolimus and combined tacrolimus-sirolimus on endothelial cells: protective effect of defibrotide. Biol Blood Marrow Transplant 2013; 19: 1439\u20131445.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt201552_CR18","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1002\/hep.510240414","volume":"24","author":"LD DeLeve","year":"1996","unstructured":"DeLeve LD . Cellular target of cyclophosphamide toxicity in the murine liver: role of glutathione and site of metabolic activation. Hepatology 1996; 24: 830\u2013837.","journal-title":"Hepatology"},{"key":"BFbmt201552_CR19","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.bbmt.2010.06.017","volume":"17","author":"S Almog","year":"2011","unstructured":"Almog S, Kurnik D, Shimoni A, Loebstein R, Hassoun E, Gopher A et al. Linearity and stability of intravenous busulfan pharmacokinetics and the role of glutathione in busulfan elimination. Biol Blood Marrow Transplant 2011; 17: 117\u2013123.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt201552_CR20","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1097\/00007890-199112000-00015","volume":"52","author":"RJ Soiffer","year":"1991","unstructured":"Soiffer RJ, Dear K, Rabinowe SN, Anderson KC, Freedman AS, Murray C et al. Hepatic dysfunction following T-cell-depleted allogeneic bone marrow transplantation. Transplantation 1991; 52: 1014\u20131019.","journal-title":"Transplantation"},{"key":"BFbmt201552_CR21","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S0301-472X(03)00070-5","volume":"31","author":"F Moscardo","year":"2003","unstructured":"Moscardo F, Urbano-Ispizua A, Sanz GF, Brunet S, Caballero D, Vallejo C et al. Positive selection for CD34+ reduces the incidence and severity of veno-occlusive disease of the liver after HLA-identical sibling allogeneic peripheral blood stem cell transplantation. Exp Hematol 2003; 31: 545\u2013550.","journal-title":"Exp Hematol"},{"key":"BFbmt201552_CR22","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1182\/blood-2003-04-1311","volume":"103","author":"WJ Hogan","year":"2004","unstructured":"Hogan WJ, Maris M, Storer B, Sandmaier BM, Maloney DG, Schoch HG et al. Hepatic injury after nonmyeloablative conditioning followed by allogeneic hematopoietic cell transplantation: a study of 193 patients. Blood 2004; 103: 78\u201384.","journal-title":"Blood"},{"key":"BFbmt201552_CR23","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1038\/bmt.2014.7","volume":"49","author":"A Nagler","year":"2014","unstructured":"Nagler A, Labopin M, Berger R, Bunjes D, Campos A, Socie G et al. Allogeneic hematopoietic SCT for adults AML using i.v. BU in the conditioning regimen: outcomes and risk factors for the occurrence of hepatic sinusoidal obstructive syndrome. Bone Marrow Transplant 2014; 49: 628\u2013633.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt201552_CR24","doi-asserted-by":"publisher","first-page":"3549","DOI":"10.1200\/JCO.2013.48.8114","volume":"31","author":"A Nagler","year":"2013","unstructured":"Nagler A, Rocha V, Labopin M, Unal A, Ben Othman T, Campos A et al. Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in remission: comparison of intravenous busulfan plus cyclophosphamide (Cy) versus total-body irradiation plus Cy as conditioning regimen\u2014a report from the acute leukemia working party of the European group for blood and marrow transplantation. J Clin Oncol 2013; 31: 3549\u20133556.","journal-title":"J Clin Oncol"},{"key":"BFbmt201552_CR25","doi-asserted-by":"publisher","first-page":"4425","DOI":"10.1182\/blood-2008-07-169342","volume":"112","author":"C Cutler","year":"2008","unstructured":"Cutler C, Stevenson K, Kim HT, Richardson P, Ho VT, Linden E et al. Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation. Blood 2008; 112: 4425\u20134431.","journal-title":"Blood"},{"key":"BFbmt201552_CR26","doi-asserted-by":"crossref","first-page":"4568","DOI":"10.1182\/blood.V92.12.4568","volume":"92","author":"H Hagglund","year":"1998","unstructured":"Hagglund H, Remberger M, Klaesson S, Lonnqvist B, Ljungman P, Ringden O . Norethisterone treatment, a major risk-factor for veno-occlusive disease in the liver after allogeneic bone marrow transplantation. Blood 1998; 92: 4568\u20134572.","journal-title":"Blood"},{"key":"BFbmt201552_CR27","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1182\/blood-2003-11-3778","volume":"104","author":"A Srivastava","year":"2004","unstructured":"Srivastava A, Poonkuzhali B, Shaji RV, George B, Mathews V, Chandy M et al. Glutathione S-transferase M1 polymorphism: a risk factor for hepatic venoocclusive disease in bone marrow transplantation. Blood 2004; 104: 1574\u20131577.","journal-title":"Blood"},{"key":"BFbmt201552_CR28","doi-asserted-by":"crossref","unstructured":"Seifert C, Wittig S, Arndt C, Gruhn B . Heparanase polymorphisms: influence on incidence of hepatic sinusoidal obstruction syndrome in children undergoing allogeneic hematopoietic stem cell transplantation. J Cancer Res Clin Oncol e-pub ahead of print 22 October 2014.","DOI":"10.1007\/s00432-014-1857-2"},{"key":"BFbmt201552_CR29","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1038\/sj.bmt.1701445","volume":"22","author":"JH Lee","year":"1998","unstructured":"Lee JH, Lee KH, Kim S, Lee JS, Kim WK, Park CJ et al. Relevance of proteins C and S, antithrombin III, von Willebrand factor, and factor VIII for the development of hepatic veno-occlusive disease in patients undergoing allogeneic bone marrow transplantation: a prospective study. Bone Marrow Transplant 1998; 22: 883\u2013888.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt201552_CR30","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1182\/blood.V80.10.2458.2458","volume":"80","author":"SI Bearman","year":"1992","unstructured":"Bearman SI, Shuhart MC, Hinds MS, McDonald GB . Recombinant human tissue plasminogen activator for the treatment of established severe venocclusive disease of the liver after bone marrow transplantation. Blood 1992; 80: 2458\u20132462.","journal-title":"Blood"},{"key":"BFbmt201552_CR31","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/sj.bmt.1705485","volume":"38","author":"S Corbacioglu","year":"2006","unstructured":"Corbacioglu S, Honig M, Lahr G, Stohr S, Berry G, Friedrich W et al. Stem cell transplantation in children with infantile osteopetrosis is associated with a high incidence of VOD, which could be prevented with defibrotide. Bone Marrow Transplant 2006; 38: 547\u2013553.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt201552_CR32","first-page":"1396","volume":"90","author":"S Cesaro","year":"2005","unstructured":"Cesaro S, Pillon M, Talenti E, Toffolutti T, Calore E, Tridello G et al. A prospective survey on incidence, risk factors and therapy of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation. Haematologica 2005; 90: 1396\u20131404.","journal-title":"Haematologica"},{"key":"BFbmt201552_CR33","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1038\/sj.bmt.1705835","volume":"40","author":"DK Cheuk","year":"2007","unstructured":"Cheuk DK, Wang P, Lee TL, Chiang AK, Ha SY, Lau YL et al. Risk factors and mortality predictors of hepatic veno-occlusive disease after pediatric hematopoietic stem cell transplantation. Bone Marrow Transplant 2007; 40: 935\u2013944.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt201552_CR34","doi-asserted-by":"publisher","first-page":"255","DOI":"10.7326\/0003-4819-118-4-199302150-00003","volume":"118","author":"GB McDonald","year":"1993","unstructured":"McDonald GB, Hinds MS, Fisher LD, Schoch HG, Wolford JL, Banaji M et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 1993; 118: 255\u2013267.","journal-title":"Ann Intern Med"},{"key":"BFbmt201552_CR35","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1182\/blood-2003-01-0255","volume":"102","author":"M Wadleigh","year":"2003","unstructured":"Wadleigh M, Richardson PG, Zahrieh D, Lee SJ, Cutler C, Ho V et al. Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood 2003; 102: 1578\u20131582.","journal-title":"Blood"},{"key":"BFbmt201552_CR36","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(11)61938-7","volume":"379","author":"S Corbacioglu","year":"2012","unstructured":"Corbacioglu S, Cesaro S, Faraci M, Valteau-Couanet D, Gruhn B, Rovelli A et al. Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial. Lancet 2012; 379: 1301\u20131309.","journal-title":"Lancet"},{"key":"BFbmt201552_CR37","doi-asserted-by":"publisher","first-page":"S88","DOI":"10.1016\/j.bbmt.2012.10.023","volume":"19","author":"PG Richardson","year":"2013","unstructured":"Richardson PG, Ho VT, Cutler C, Glotzbecker B, Antin JH, Soiffer R . Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: novel insights to pathogenesis, current status of treatment, and future directions. Biol Blood Marrow Transplant 2013; 19: S88\u2013S90.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt201552_CR38","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1200\/JCO.1993.11.9.1729","volume":"11","author":"SI Bearman","year":"1993","unstructured":"Bearman SI, Anderson GL, Mori M, Hinds MS, Shulman HM, McDonald GB . Venoocclusive disease of the liver: development of a model for predicting fatal outcome after marrow transplantation. J Clin Oncol 1993; 11: 1729\u20131736.","journal-title":"J Clin Oncol"},{"key":"BFbmt201552_CR39","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1111\/bjh.12558","volume":"163","author":"FL Dignan","year":"2013","unstructured":"Dignan FL, Wynn RF, Hadzic N, Karani J, Quaglia A, Pagliuca A et al. BCSH\/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation. Br J Haematol 2013; 163: 444\u2013457.","journal-title":"Br J Haematol"},{"key":"BFbmt201552_CR40","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/BF01695888","volume":"66","author":"E Carreras","year":"1993","unstructured":"Carreras E, Granena A, Navasa M, Bruguera M, Marco V, Sierra J et al. On the reliability of clinical criteria for the diagnosis of hepatic veno-occlusive disease. Ann Hematol 1993; 66: 77\u201380.","journal-title":"Ann Hematol"},{"key":"BFbmt201552_CR41","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1002\/cncr.29087","volume":"121","author":"M Mohty","year":"2014","unstructured":"Mohty M, Malard F, Blaise D, Milpied N, Furst S, Tabrizi R et al. Reduced-toxicity conditioning with fludarabine, once-daily intravenous busulfan, and antithymocyte globulins prior to allogeneic stem cell transplantation: Results of a multicenter prospective phase 2 trial. Cancer 2014; 121: 562\u2013569.","journal-title":"Cancer"},{"key":"BFbmt201552_CR42","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1182\/blood-2004-02-0414","volume":"104","author":"M de Lima","year":"2004","unstructured":"de Lima M, Couriel D, Thall PF, Wang X, Madden T, Jones R et al. Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood 2004; 104: 857\u2013864.","journal-title":"Blood"},{"key":"BFbmt201552_CR43","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1038\/bmt.2010.137","volume":"46","author":"N Cantoni","year":"2011","unstructured":"Cantoni N, Gerull S, Heim D, Halter J, Bucher C, Buser A et al. Order of application and liver toxicity in patients given BU and CY containing conditioning regimens for allogeneic hematopoietic SCT. Bone Marrow Transplant 2011; 46: 344\u2013349.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt201552_CR44","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/sj.bmt.1705297","volume":"37","author":"H Imran","year":"2006","unstructured":"Imran H, Tleyjeh IM, Zirakzadeh A, Rodriguez V, Khan SP . Use of prophylactic anticoagulation and the risk of hepatic veno-occlusive disease in patients undergoing hematopoietic stem cell transplantation: a systematic review and meta-analysis. Bone Marrow Transplant 2006; 37: 677\u2013686.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt201552_CR45","doi-asserted-by":"crossref","first-page":"2834","DOI":"10.1182\/blood.V79.11.2834.bloodjournal79112834","volume":"79","author":"M Attal","year":"1992","unstructured":"Attal M, Huguet F, Rubie H, Huynh A, Charlet JP, Payen JL et al. Prevention of hepatic veno-occlusive disease after bone marrow transplantation by continuous infusion of low-dose heparin: a prospective, randomized trial. Blood 1992; 79: 2834\u20132840.","journal-title":"Blood"},{"key":"BFbmt201552_CR46","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1097\/00007890-199604150-00014","volume":"61","author":"R Or","year":"1996","unstructured":"Or R, Nagler A, Shpilberg O, Elad S, Naparstek E, Kapelushnik J et al. Low molecular weight heparin for the prevention of veno-occlusive disease of the liver in bone marrow transplantation patients. Transplantation 1996; 61: 1067\u20131071.","journal-title":"Transplantation"},{"key":"BFbmt201552_CR47","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1111\/j.1600-0609.1991.tb01859.x","volume":"47","author":"L Marsa-Vila","year":"1991","unstructured":"Marsa-Vila L, Gorin NC, Laporte JP, Labopin M, Dupuy-Montbrun MC, Fouillard L et al. Prophylactic heparin does not prevent liver veno-occlusive disease following autologous bone marrow transplantation. Eur J Haematol 1991; 47: 346\u2013354.","journal-title":"Eur J Haematol"},{"key":"BFbmt201552_CR48","doi-asserted-by":"publisher","first-page":"975","DOI":"10.7326\/0003-4819-128-12_Part_1-199806150-00002","volume":"128","author":"JH Essell","year":"1998","unstructured":"Essell JH, Schroeder MT, Harman GS, Halvorson R, Lew V, Callander N et al. Ursodiol prophylaxis against hepatic complications of allogeneic bone marrow transplantation. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998; 128: 975\u2013981.","journal-title":"Ann Intern Med"},{"key":"BFbmt201552_CR49","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/(SICI)1096-8652(200005)64:1<32::AID-AJH6>3.0.CO;2-N","volume":"64","author":"K Ohashi","year":"2000","unstructured":"Ohashi K, Tanabe J, Watanabe R, Tanaka T, Sakamaki H, Maruta A et al. The Japanese multicenter open randomized trial of ursodeoxycholic acid prophylaxis for hepatic veno-occlusive disease after stem cell transplantation. Am J Hematol 2000; 64: 32\u201338.","journal-title":"Am J Hematol"},{"key":"BFbmt201552_CR50","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.bbmt.2006.09.012","volume":"13","author":"J Tay","year":"2007","unstructured":"Tay J, Tinmouth A, Fergusson D, Huebsch L, Allan DS . Systematic review of controlled clinical trials on the use of ursodeoxycholic acid for the prevention of hepatic veno-occlusive disease in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2007; 13: 206\u2013217.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt201552_CR51","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/sj.bmt.1703342","volume":"29","author":"SH Park","year":"2002","unstructured":"Park SH, Lee MH, Lee H, Kim HS, Kim K, Kim WS et al. A randomized trial of heparin plus ursodiol vs. heparin alone to prevent hepatic veno-occlusive disease after hematopoietic stem cell transplantation. Bone Marrow Transplant 2002; 29: 137\u2013143.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt201552_CR52","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1182\/blood-2001-12-0159","volume":"100","author":"T Ruutu","year":"2002","unstructured":"Ruutu T, Eriksson B, Remes K, Juvonen E, Volin L, Remberger M et al. Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation. Blood 2002; 100: 1977\u20131983.","journal-title":"Blood"},{"key":"BFbmt201552_CR53","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1056\/NEJMoa1004383","volume":"363","author":"TA Gooley","year":"2010","unstructured":"Gooley TA, Chien JW, Pergam SA, Hingorani S, Sorror ML, Boeckh M et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med 2010; 363: 2091\u20132101.","journal-title":"N Engl J Med"},{"key":"BFbmt201552_CR54","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1038\/sj.bmt.1702386","volume":"25","author":"D Azoulay","year":"2000","unstructured":"Azoulay D, Castaing D, Lemoine A, Hargreaves GM, Bismuth H . Transjugular intrahepatic portosystemic shunt (TIPS) for severe veno-occlusive disease of the liver following bone marrow transplantation. Bone Marrow Transplant 2000; 25: 987\u2013992.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt201552_CR55","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1034\/j.1600-6143.2002.20815.x","volume":"2","author":"ID Kim","year":"2002","unstructured":"Kim ID, Egawa H, Marui Y, Kaihara S, Haga H, Lin YW et al. A successful liver transplantation for refractory hepatic veno-occlusive disease originating from cord blood transplantation. Am J Transplant 2002; 2: 796\u2013800.","journal-title":"Am J Transplant"},{"key":"BFbmt201552_CR56","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1517\/14740338.2012.749855","volume":"12","author":"PG Richardson","year":"2013","unstructured":"Richardson PG, Corbacioglu S, Ho VT, Kernan NA, Lehmann L, Maguire C et al. Drug safety evaluation of defibrotide. Expert Opin Drug Saf 2013; 12: 123\u2013136.","journal-title":"Expert Opin Drug Saf"},{"key":"BFbmt201552_CR57","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.bbmt.2010.02.009","volume":"16","author":"PG Richardson","year":"2010","unstructured":"Richardson PG, Soiffer RJ, Antin JH, Uno H, Jin Z, Kurtzberg J et al. Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial. Biol Blood Marrow Transplant 2010; 16: 1005\u20131017.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt201552_CR58","first-page":"654","volume":"114","author":"P Richardson","year":"2009","unstructured":"Richardson P, Tomblyn M, Kernan N, Brochstein JA, Mineishi S, Termuhlen A et al. Results of a Phase 3 study utilizing a historical control. Defibrotide (DF) in the treatment of severe hepatic veno-occlusive disease (VOD) with multi-organ failure (MOF) following stem cell transplantation (SCT). ASH Annual Meeting Abstracts 2009; 114: 654.","journal-title":"ASH Annual Meeting Abstracts"},{"key":"BFbmt201552_CR59","first-page":"700","volume":"122","author":"PG Richardson","year":"2013","unstructured":"Richardson PG, Smith AR, Triplett BM, Kernan NA, Grupp SA, Arai S et al. Results of the large prospective study on the use of defibrotide (DF) in the treatment of hepatic veno-occlusive disease (VOD) in hematopoietic stem cell transplant (HSCT). Early intervention improves outcome - updated results of a treatment IND (T-IND) expanded access protocol. ASH Annual Meeting Abstracts 2013; 122: 700\u2013700.","journal-title":"ASH Annual Meeting Abstracts"},{"key":"BFbmt201552_CR60","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.bbmt.2014.04.021","volume":"20","author":"F Malard","year":"2014","unstructured":"Malard F, Chevallier P, Guillaume T, Delaunay J, Rialland F, Harousseau JL et al. Continuous reduced nonrelapse mortality after allogeneic hematopoietic stem cell transplantation: A single-institution's three decade experience. Biol Blood Marrow Transplant 2014; 20: 1217\u20131223.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt201552_CR61","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","volume":"14","author":"L Luznik","year":"2008","unstructured":"Luznik L, O'Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2008; 14: 641\u2013650.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt201552_CR62","doi-asserted-by":"publisher","first-page":"5675","DOI":"10.1200\/JCO.2005.07.061","volume":"23","author":"C Schmid","year":"2005","unstructured":"Schmid C, Schleuning M, Ledderose G, Tischer J, Kolb HJ . Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol 2005; 23: 5675\u20135687.","journal-title":"J Clin Oncol"},{"key":"BFbmt201552_CR63","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1182\/blood.V124.21.1228.1228","volume":"124","author":"M Mohty","year":"2014","unstructured":"Mohty M, Malard F, Blaise D, Milpied N, Socie G, Huynh A et al. Sequential regimen of clofarabine, cytarabine and reduced intensity conditioning (RIC) prior to allogeneic stem cell transplantation (allo-SCT) for acute myeloid leukemia (AML) in primary treatment failure. Blood 2014; 124: 1228\u20131228.","journal-title":"Blood"},{"key":"BFbmt201552_CR64","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1038\/bmt.2014.15","volume":"49","author":"S Dirou","year":"2014","unstructured":"Dirou S, Malard F, Chambellan A, Chevallier P, Germaud P, Guillaume T et al. Stable long-term pulmonary function after fludarabine, antithymocyte globulin and i.v. BU for reduced-intensity conditioning allogeneic SCT. Bone Marrow Transplant 2014; 49: 622\u2013627.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt201552_CR65","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1038\/bmt.2008.99","volume":"41","author":"NS Majhail","year":"2008","unstructured":"Majhail NS, Lazarus HM, Burns LJ . Iron overload in hematopoietic cell transplantation. Bone Marrow Transplant 2008; 41: 997\u20131003.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt201552_CR66","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1182\/blood-2013-04-499772","volume":"122","author":"BJ Trottier","year":"2013","unstructured":"Trottier BJ, Burns LJ, DeFor TE, Cooley S, Majhail NS . Association of iron overload with allogeneic hematopoietic cell transplantation outcomes: a prospective cohort study using R2-MRI-measured liver iron content. Blood 2013; 122: 1678\u20131684.","journal-title":"Blood"},{"key":"BFbmt201552_CR67","first-page":"737","volume":"92","author":"PG Richardson","year":"1998","unstructured":"Richardson PG, Elias AD, Krishnan A, Wheeler C, Nath R, Hoppensteadt D et al. Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population. Blood 1998; 92: 737\u2013744.","journal-title":"Blood"},{"key":"BFbmt201552_CR68","doi-asserted-by":"publisher","first-page":"4337","DOI":"10.1182\/blood-2002-04-1216","volume":"100","author":"PG Richardson","year":"2002","unstructured":"Richardson PG, Murakami C, Jin Z, Warren D, Momtaz P, Hoppensteadt D et al. Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome. Blood 2002; 100: 4337\u20134343.","journal-title":"Blood"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/bmt201552.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bmt201552","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bmt201552.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T13:42:23Z","timestamp":1684417343000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bmt201552"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,23]]},"references-count":68,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["BFbmt201552"],"URL":"https:\/\/doi.org\/10.1038\/bmt.2015.52","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,23]]},"assertion":[{"value":"30 December 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors designed the manuscript, analyzed the literature, wrote and commented on the manuscript. All authors approved submission of the manuscript for publication purposes. All authors received honoraria and\/or research support from JAZZ Pharmaceuticals whose product is discussed in this manuscript. JAZZ pharmaceuticals provided an unrestricted educational grant for support for the current study, but did not participate to conduct, data\/results analyses or manuscript writing.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}